Technology area: Biotechnology & Pharmaceuticals
24 pending office actions • 6 art units • 19 examiners • 0 of 24 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
Ionis Pharmaceuticals Inc. has 22 pending office actions in Biotechnology & Pharmaceuticals. The matters span 18 examiners and 6 art units, creating a broad examination footprint that calls for docket coordination across multiple technical and procedural settings.
POLIAKOVA-GEORGAN, EKATERINA is the busiest examiner, with 3 pending matters. That assignment is the largest identified examiner workload, but it represents only part of the overall docket, so centralized tracking should preserve matter-specific strategies while monitoring recurring issues across the portfolio.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (21%) |
| §112 only | 4 (17%) |
| Double-patenting only | 2 (8%) |
| Double-patenting + other | 3 (12%) |
| Multi-statute (no §101) | 10 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 3 | 63.9% | +18.1% |
| SHIN, DANA H | 3 | 26.9% | +26.9% |
| ARIETI, RUTH SOPHIA | 2 | 46.2% | +71.4% |
| VYAS, KEYUR ANILKUMAR | 1 | 50.0% | +58.7% |
| WHITEMAN, BRIAN A | 1 | 68.4% | +16.8% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
| RYAN, DOUGLAS CHARLES | 1 | 38.2% | +48.4% |
| TATGE, LEXUS MARC | 1 | 25.0% | +100.0% |
| MEYERING, SHABANA SHABBEER | 1 | 68.5% | +45.1% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998141 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | ROSSI, JULIA ANNE LORRAIN | 67d overdue |
| 17611780 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | ARIETI, RUTH SOPHIA | 60d overdue |
| 18001241 | COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION | SHIN, DANA H | 30d overdue |
| 18263194 | COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN | TATGE, LEXUS MARC | 13d |
| 18569084 | MODULATION OF NOX4 EXPRESSION | VANHORN, ABIGAIL LOUISE | — |
| 18448392 | Selective Antisense Compounds and Uses Thereof | SHIN, DANA H | — |
| 18264705 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | RYAN, DOUGLAS CHARLES | — |
| 18363244 | Compounds and Methods for Modulating Splicing of Pre-MRNA | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18443619 | COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION | VYAS, KEYUR ANILKUMAR | 282d overdue |
| 17611780 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | ARIETI, RUTH SOPHIA | 60d overdue |
| 18001241 | COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION | SHIN, DANA H | 30d overdue |
| 17372173 | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | POLIAKOVA-GEORGAN, EKATERINA | 10d overdue |
| 18262438 | COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION | KONOPKA, CATHERINE ANNE | 8d overdue |
| 18247567 | METHODS FOR REDUCING APOCIII EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | 4d overdue |
| 18263194 | COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN | TATGE, LEXUS MARC | 13d |
| 18431253 | Modulators of Complement Factor B | WHITEMAN, BRIAN A | — |
| Art Unit | Apps |
|---|---|
| 1637 | 9 |
| 1635 | 9 |
| 1636 | 3 |
| 1615 | 1 |
| 1634 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18443619 | COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Final Rejection | 282d overdue | Pending | Feb 16, 2024 |
| 18431253 | Modulators of Complement Factor B | WHITEMAN, BRIAN A | 1636 | §112DP | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18569084 | MODULATION OF NOX4 EXPRESSION | VANHORN, ABIGAIL LOUISE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18457941 | MODULATORS OF PNPLA3 EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §112Other | Non-Final OA | — | Pending | Aug 29, 2023 |
| 18448392 | Selective Antisense Compounds and Uses Thereof | SHIN, DANA H | 1635 | DP | Final Rejection | — | Pending | Aug 11, 2023 |
| 18264705 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | RYAN, DOUGLAS CHARLES | 1635 | §103§112 | Non-Final OA | — | Pending | Aug 08, 2023 |
| 18363244 | Compounds and Methods for Modulating Splicing of Pre-MRNA | SHIN, DANA H | 1635 | §102§103§112Other | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18263194 | COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN | TATGE, LEXUS MARC | 1637 | §103 | Non-Final OA | 13d | Pending | Jul 27, 2023 |
| 18358591 | COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION | MEYERING, SHABANA SHABBEER | 1635 | §102§103 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18262438 | COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION | KONOPKA, CATHERINE ANNE | 1635 | §112 | Final Rejection | 8d overdue | Pending | Jul 21, 2023 |
| 18247567 | METHODS FOR REDUCING APOCIII EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103Other | Non-Final OA | 4d overdue | Pending | Mar 31, 2023 |
| 18247311 | COMPOUNDS FOR MODULATING CHMP7 | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103§112 | Non-Final OA | — | Pending | Mar 30, 2023 |
| 18001241 | COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION | SHIN, DANA H | 1635 | §112 | Final Rejection | 30d overdue | Pending | Dec 08, 2022 |
| 17998141 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | ROSSI, JULIA ANNE LORRAIN | 1615 | §103§112 | Final Rejection | 67d overdue | Pending | Nov 07, 2022 |
| 17908135 | COMPOUNDS AND METHODS FOR MODULATING KCNQ2 | CHONG, KIMBERLY | 1636 | §102§103§112 | Non-Final OA | — | Pending | Aug 30, 2022 |
| 17850456 | MODIFIED CRISPR RNA AND MODIFIED SINGLE CRISPR RNA AND USES THEREOF | MARVICH, MARIA | 1634 | §102§112Other | Non-Final OA | — | Pending | Jun 27, 2022 |
| 17635096 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | VIVLEMORE, TRACY ANN | 1600 | §103 | Non-Final OA | — | Pending | Feb 14, 2022 |
| 17611780 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | ARIETI, RUTH SOPHIA | 1635 | §103§112Other | Non-Final OA | 60d overdue | Pending | Nov 16, 2021 |
| 17508516 | COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION | ZARA, JANE J | 1637 | §102§103§112 | Non-Final OA | — | Pending | Oct 22, 2021 |
| 17389599 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION | ARIETI, RUTH SOPHIA | 1635 | DP | Non-Final OA | — | Pending | Jul 30, 2021 |
| 17424672 | COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION | PERSONS, JENNA L | 1637 | §102§103DP | Non-Final OA | 66d overdue | Pending | Jul 21, 2021 |
| 17372173 | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103 | Final Rejection | 10d overdue | Pending | Jul 09, 2021 |
| 17291199 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS | QIAN, CELINE X | 1637 | §112 | Non-Final OA | 4d overdue | Pending | May 04, 2021 |
| 17282335 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112DP | Non-Final OA | — | Pending | Apr 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIonis Pharmaceuticals Inc. has 24 pending office actions as of October 2026, spread across 6 art units and 19 examiners.
Ekaterina Poliakova-Georgan has the most, with 3 of Ionis Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
